ITMI20041772A1 - Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione. - Google Patents

Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione.

Info

Publication number
ITMI20041772A1
ITMI20041772A1 IT001772A ITMI20041772A ITMI20041772A1 IT MI20041772 A1 ITMI20041772 A1 IT MI20041772A1 IT 001772 A IT001772 A IT 001772A IT MI20041772 A ITMI20041772 A IT MI20041772A IT MI20041772 A1 ITMI20041772 A1 IT MI20041772A1
Authority
IT
Italy
Prior art keywords
thiamine
learning
defects
treatment
pathologies linked
Prior art date
Application number
IT001772A
Other languages
English (en)
Inventor
Michele Bonanomi
Bruno Silvestrini
Original Assignee
Bioprogress Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprogress Spa filed Critical Bioprogress Spa
Priority to IT001772A priority Critical patent/ITMI20041772A1/it
Publication of ITMI20041772A1 publication Critical patent/ITMI20041772A1/it
Priority to US11/663,131 priority patent/US20080311200A1/en
Priority to CA002580330A priority patent/CA2580330A1/en
Priority to EP05733449A priority patent/EP1811972A1/en
Priority to PCT/IB2005/001206 priority patent/WO2006030260A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IT001772A 2004-09-17 2004-09-17 Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione. ITMI20041772A1 (it)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IT001772A ITMI20041772A1 (it) 2004-09-17 2004-09-17 Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione.
US11/663,131 US20080311200A1 (en) 2004-09-17 2005-05-02 Controlled Slow Release Formulation of Thiamine and Use Thereof in the Treatment of Pathologies Connected to Defective Process of Learning and Memorization
CA002580330A CA2580330A1 (en) 2004-09-17 2005-05-02 A controlled slow release formulation of thiamine and use thereof in the treatment of pathologies connected to defective process of learning and memorization
EP05733449A EP1811972A1 (en) 2004-09-17 2005-05-02 A controlled slow release formulation of thiamine and use thereof in the treatment of pathologies connected to defective process of learning and memorization
PCT/IB2005/001206 WO2006030260A1 (en) 2004-09-17 2005-05-02 A controlled slow release formulation of thiamine and use thereof in the treatment of pathologies connected to defective process of learning and memorization

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001772A ITMI20041772A1 (it) 2004-09-17 2004-09-17 Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione.

Publications (1)

Publication Number Publication Date
ITMI20041772A1 true ITMI20041772A1 (it) 2004-12-17

Family

ID=34968626

Family Applications (1)

Application Number Title Priority Date Filing Date
IT001772A ITMI20041772A1 (it) 2004-09-17 2004-09-17 Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione.

Country Status (5)

Country Link
US (1) US20080311200A1 (it)
EP (1) EP1811972A1 (it)
CA (1) CA2580330A1 (it)
IT (1) ITMI20041772A1 (it)
WO (1) WO2006030260A1 (it)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577512A (en) * 1968-10-11 1971-05-04 Nat Patent Dev Corp Sustained release tablets
JPS61151133A (ja) * 1984-12-25 1986-07-09 Toyo Jozo Co Ltd 遅延放出性被覆組成物及びこれにより被覆した被覆製剤
JPS63222112A (ja) * 1987-03-10 1988-09-16 Nippon Soda Co Ltd 徐放性顆粒
JPH01308232A (ja) * 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 固型医薬およびその製造法
DE69124223T2 (de) * 1990-02-05 1997-04-30 Lifescience Corp Vitamine und mineralien enthaltende nahrungszusätze
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5167964A (en) * 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
US6488956B1 (en) * 1994-06-20 2002-12-03 Drugtech Corporation Multi-vitamin and mineral supplements for women
US6352713B1 (en) * 1999-12-01 2002-03-05 Drugtech Corporation Nutritional composition
US5869084A (en) * 1994-06-20 1999-02-09 K-V Pharmaceuticals Co. Multi-vitamin and mineral supplements for women
US5843469A (en) * 1997-04-11 1998-12-01 Mcentee; William J. Lipid soluble forms of thiamine for prevention and treatment of age-related cognitive impairment of the nervous system
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US6191162B1 (en) * 1998-05-28 2001-02-20 Medical Research Institute Method of reducing serum glucose levels
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US20040259895A1 (en) * 1998-05-28 2004-12-23 Medical Research Institute Oral formulation of lipid soluble thiamine and lipoic acid
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
US6245360B1 (en) * 1998-06-26 2001-06-12 John S. Markowitz Nutritional supplement

Also Published As

Publication number Publication date
US20080311200A1 (en) 2008-12-18
WO2006030260A1 (en) 2006-03-23
CA2580330A1 (en) 2006-03-23
EP1811972A1 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
LU93081I2 (fr) Ambrisentan utilisé en traitement combiné avec tadalafil
GB2431539B (en) Intubation assistance apparatus and intubation assistance used in the apparatus
PL2468290T3 (pl) Antagoniści aktywiny-ActRII do stosowania w leczeniu niedokrwistości
DE602007004842D1 (de) Vorrichtung zur Unterstützung bei der Herzbehandlung
EP1867416A4 (en) Edge replacement cutter tip and method of manufacturing the same
DE602006007336D1 (de) Umspritzte behälter und verfahren zu deren herstellung
EP1922637A4 (en) FORMATION OF NEURAL FOLDING NETWORKS ON GRAPHICS PROCESSING UNITS
RS55174B1 (sr) Formulacija i metod obložene tablete
BRPI0718429A2 (pt) Suspensões aquosas farmacêuticas contendo o rebamipide e processo para a fabricação das mesmas
IL197240A0 (en) Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
DK1919450T3 (da) Antihistamin- og corticosteroidholdig liposomsammensætning og dens anvendelse til fremstilling af et lægemiddel til behandling af rhinitis og beslægtede lidelser
JP2009039101A5 (it)
IL191317A (en) Use of cells for the preparation of a pharmaceutical preparation for complementary treatment
HUE043175T2 (hu) Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében
SI2432798T1 (sl) Derivat 17-hidroksi-17-pentafluoretil-estra-4,9(10)-dien-11-arila, postopki izdelave in uporaba pri zdravljenju bolezni
DE602004020660D1 (de) Pyrazolylderivative in form von arzneimitteln zur behandlung von akuten oder chronischen neuronalen regressionen
EP1930385A4 (en) AQUEOUS SURFACE TREATMENT AND SURFACE TREATED CONSTRUCTION
EP1902406A4 (en) BIOMETRIC DRUG CONTAINER
EP2148667A4 (en) USE OF CYCLOHEXANHEXOL DERIVATIVES IN THE TREATMENT OF EYE DISEASES
ITMI20052085A1 (it) Tutore ambidestro per polso provvisto di immobilizzatore del pollice
DE502006006768D1 (de) MIM-Kondensator sowie zugehöriges Herstellungsverfahren
EP1813592A4 (en) CAGE-FORMED CYCLOBUTANOIC DIANHYDRIDES AND PROCESS FOR THE SYNTHESIS OF THESE COMPOUNDS
DE602004018913D1 (de) Cachespeicher-Steuereinheit und -Steuerverfahren
EP1954767A4 (en) Titanium dioxide finishing process
ITMI20041772A1 (it) Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione.